Ghanei Mostafa, Abolmaali Kamran, Aslani Jafar
Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University, Tehran, Iran.
Curr Ther Res Clin Exp. 2004 Nov;65(6):495-504. doi: 10.1016/j.curtheres.2004.12.001.
Victims of sulfur mustard (SM) gas exposure experience different types of chronic pulmonary disease, manifested as cough, sputum production, and dyspnea. Conventional therapies (eg, immunosuppressive drugs, corticosteroids) have not been effective in these patients.
This study was carried out to determine the efficacy of concomitant administration of the macrolide clarithromycin and the mucolytic agent acetylcysteine in the treatment of bronchiolitis obliterans in SM-exposed patients.
This open-label clinical study was conducted at the Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University, Tehran, Iran. Clarithromycin and acetylcysteine were administered concomitantly for 6 months to male SM-exposed patients with chronic bronchitis and bronchiolitis obliterans who were nonresponsive to conventional treatments. Efficacy analysis included symptom assessment and pulmonary function tests (forced expiratory volume in 1 second [FEV1], forced vital capacity [FVC], and FEV1/FVC ratio) using spirometry, performed at baseline and after 2 and 6 months of treatment.
Seventeen male patients (mean [SD] age, 38.3 [5.3] years [range, 31-50 years]; mean [SD] body weight, 77.9 [15.7] kg) were included in the study. Cough and sputum production were each found in 10 of 17 patients (58.8%) at baseline and were improved in all 10 patients after the administration of clarithromycin and acetylcysteine. FEV1 and FVC also were improved, by mean (SD) 10.6% (9.7%) (P < 0.001 vs baseline) and 12.9% (13.6%) (P = 0.001 vs baseline). No significant change in FEV1/FVC ratio was found.
In this study of concomitant administration of clarithromycin and acetylcysteine for the treatment of bronchiolitis obliterans in SM-exposed patients, symptoms and pulmonary function were improved. These results may have been related to the therapeutic effects of a macrolide antibiotic on chronic bronchitis and bronchiolitis obliterans in these patients. Based on the results of this study, we recommend this treatment for chemical warfare victims with recurrent exacerbation of bronchitis who do not respond to conventional treatment.
硫芥气中毒受害者会患上不同类型的慢性肺部疾病,表现为咳嗽、咳痰和呼吸困难。传统疗法(如免疫抑制药物、皮质类固醇)对这些患者无效。
本研究旨在确定大环内酯类药物克拉霉素与黏液溶解剂乙酰半胱氨酸联合给药治疗硫芥气中毒患者闭塞性细支气管炎的疗效。
这项开放标签的临床研究在伊朗德黑兰的巴基耶塔拉医科大学化学损伤研究中心进行。克拉霉素和乙酰半胱氨酸联合给药6个月,用于治疗对传统治疗无反应的患有慢性支气管炎和闭塞性细支气管炎的男性硫芥气中毒患者。疗效分析包括症状评估和肺功能测试(第1秒用力呼气量[FEV1]、用力肺活量[FVC]和FEV1/FVC比值),使用肺活量测定法,在基线以及治疗2个月和6个月后进行。
17名男性患者(平均[标准差]年龄,38.3[5.3]岁[范围31 - 50岁];平均[标准差]体重,77.9[15.7]kg)纳入研究。17名患者中有10名(58.8%)在基线时出现咳嗽和咳痰症状,在给予克拉霉素和乙酰半胱氨酸后,所有10名患者的症状均有所改善。FEV1和FVC也有所改善,平均(标准差)分别提高了10.6%(9.7%)(与基线相比P < 0.001)和12.9%(13.6%)(与基线相比P = 0.001)。FEV1/FVC比值未发现显著变化。
在本研究中,克拉霉素和乙酰半胱氨酸联合给药治疗硫芥气中毒患者的闭塞性细支气管炎,症状和肺功能均得到改善。这些结果可能与大环内酯类抗生素对这些患者慢性支气管炎和闭塞性细支气管炎的治疗作用有关。基于本研究结果,我们建议对传统治疗无反应的反复加重性支气管炎的化学战受害者采用这种治疗方法。